ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer

Non‐small cell lung cancer (NSCLC) patients harboring EGFR sensitive mutations may benefit from treatment with EGFR TKIs. Osimertinib, which is an irreversible third‐generation EGFR TKI, has demonstrated a convincing efficacy, irrespective of whether it is used in first‐ or second‐line treatment. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Helei, Sun, Dantong, Zhang, Chuantao, Liu, Dong, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952795/
https://www.ncbi.nlm.nih.gov/pubmed/33506568
http://dx.doi.org/10.1111/1759-7714.13817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952795/
https://www.ncbi.nlm.nih.gov/pubmed/33506568
http://dx.doi.org/10.1111/1759-7714.13817

Ejemplares similares